Palforzia

RSS

defatted powder of Arachis hypogaea L., semen (peanuts)

Authorised
This medicine is authorised for use in the European Union.

Overview

Palforzia is a medicine for treating peanut allergy in children from 4 to 17 years of age and patients who become adults whilst on treatment. While taking this medicine, patients continue avoiding peanuts.

Palforzia contains peanut powder.

This EPAR was last updated on 21/12/2020

Authorisation details

Product details
Name
Palforzia
Agency product number
EMEA/H/C/004917
Active substance
defatted powder of Arachis hypogaea L., semen (peanuts)
International non-proprietary name (INN) or common name
defatted powder of Arachis hypogaea L., semen (peanuts)
Therapeutic area (MeSH)
Peanut Hypersensitivity
Anatomical therapeutic chemical (ATC) code
V01
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Aimmune Therapeutics Ireland Limited
Date of issue of marketing authorisation valid throughout the European Union
17/12/2020
Contact address

Block B The Crescent Building
Northwood Crescent Northwood
Dublin 9 Co.
Dublin D09 C6X8
Ireland

Product information

17/12/2020 Palforzia - EMEA/H/C/004917 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Allergens

Therapeutic indication

Palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia may be continued in patients 18 years of age and older.

Palforzia should be used in conjunction with a peanut-avoidant diet.

Assessment history

How useful was this page?

Add your rating